Company / Cash & Equivalents
MESA LABORATORIES INC /CO/ Cash & Equivalents History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$26.9M
FY2026
5-year range
$26.9M / $49.3M
FY2022-FY2026
Trend
-1.4%
vs FY2025
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 5 consecutive years, from $264M in FY2021 to $27M in FY2026.
Based on SEC 10-K filings.
$27M in FY2026 with a 5-year CAGR of -36.6%.
Declined from $28M to $27M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -6.5%
- 5-Year CAGR
- -36.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- MESA LABORATORIES INC /CO/'s cash & equivalents has declined for 5 consecutive years.
- 5-year CAGR of -36.6%, indicating a declining trend.
- In FY2026, cash & equivalents decreased 1.4% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.03 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | $26.9M | -1.4% |
| FY2025 | $27.3M | -3.2% |
| FY2024 | $28.2M | -14.3% |
| FY2023 | $32.9M | -33.3% |
| FY2022 | $49.3M | -81.3% |
| FY2021 | $263.9M | +224.2% |
| FY2020 | $81.4M | +699.0% |
| FY2019 | $10.2M | +86.2% |
| FY2018 | $5.5M | -6.0% |
| FY2017 | $5.8M | +2.2% |
As of FY2026 · SEC 10-K · Updated Jun 28, 2026